https://mindmedicinelaw.com/briefing/ketamine-liability-concerns-legal-pressures-on-u-s-clinics-20261011-49143The Psychedelic Journalen2026-10-11T22:04:30.662819+00:00Ketamine Liability Concerns: Legal Pressures on U.S. Clinicsketamine liability, psychedelic law, ketamine clinics, off-label use, malpractice risk, insurance coverage, standard of care, psychedelic policy, clinical guidelineshttps://mindmedicinelaw.com/briefing/psychedelics-and-sleep-architecture-systematic-review-insights-20261010-48890The Psychedelic Journalen2026-10-11T15:04:44.626535+00:00Psychedelics and Sleep Architecture: Systematic Review Insightspsychedelics, sleep architecture, REM sleep, psilocybin, LSD, ayahuasca, clinical trials, sleep disruption, neuroplasticity, therapeutic mechanismshttps://mindmedicinelaw.com/briefing/swedish-cannabis-use-underestimated-implications-for-policy-reform-20261009-48892The Psychedelic Journalen2026-10-11T15:06:43.224558+00:00Swedish Cannabis Use Underestimated: Implications for Policy Reformcannabis use prevalence, sweden drug policy, cannabis use disorder, survey methodology, healthcare needs, decriminalization impact, public health surveillance, psychedelic policy implicationshttps://mindmedicinelaw.com/briefing/nicotine-s-amplification-of-fentanyl-dopamine-effects-implications-for-oud-risk-20261009-48899The Psychedelic Journalen2026-10-11T15:06:28.201852+00:00Nicotine’s Amplification of Fentanyl Dopamine Effects: Implications for OUD Risknicotine, fentanyl, dopamine transmission, dorsal lateral striatum, opioid use disorder, polysubstance use, addiction neuroscience, public health policy, clinical trialshttps://mindmedicinelaw.com/briefing/psychedelics-in-neurosurgery-promise-evidence-gaps-and-translational-barriers-20261009-48878The Psychedelic Journalen2026-10-11T15:05:39.020236+00:00Psychedelics in Neurosurgery: Promise, Evidence Gaps, and Translational Barrierspsychedelics in neurosurgery, esketamine perioperative use, psilocybin cancer distress, neuroplasticity, clinical trial design, safety barriers, regulatory approval, perioperative care, pain management, neurorehabilitationhttps://mindmedicinelaw.com/briefing/il-6-sgp130-trans-signaling-a-new-mechanism-in-trd-pathogenesis-20261009-48900The Psychedelic Journalen2026-10-11T15:05:21.743873+00:00IL-6 sgp130 Trans-signaling: A New Mechanism in TRD Pathogenesisil-6 trans-signaling, sgp130 buffer, treatment-resistant depression, immunopsychiatry, biomarker stratification, precision psychiatry, sgp130fc, clinical trial design, psychedelic-assisted therapy, neuroinflammationhttps://mindmedicinelaw.com/briefing/germany-s-dzpg-model-systems-a-new-era-for-mechanistic-mental-health-research-20261009-48902The Psychedelic Journalen2026-10-11T15:05:02.836143+00:00Germany's DZPG Model Systems: A New Era for Mechanistic Mental Health Researchdzpg, germany, model systems, mental health research, psychedelic research, animal models, ipsc, high-throughput screening, translational science, public involvementhttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-safety-during-breastfeeding-systematic-review-insights-20261009-48565The Psychedelic Journalen2026-10-10T15:08:05.018596+00:00Ketamine and Esketamine Safety During Breastfeeding: Systematic Review Insightsketamine, esketamine, breastfeeding safety, pharmacokinetics, infant outcomes, systematic review, perinatal psychiatry, lactation guidelines, public health, clinical researchhttps://mindmedicinelaw.com/briefing/techbio-3-0-ai-driven-closed-loop-drug-discovery-in-psychedelics-20261009-48581The Psychedelic Journalen2026-10-10T15:07:47.840550+00:00TechBio 3.0: AI-Driven Closed-Loop Drug Discovery in Psychedelicstechbio 3.0, ai drug discovery, generative chemistry, automated experimentation, psychedelic research, cns drug development, regulatory policy, closed-loop systems, fda, drug discovery automationhttps://mindmedicinelaw.com/briefing/blinding-ethics-and-safety-in-psychedelic-clinical-trials-20261009-48643The Psychedelic Journalen2026-10-10T15:07:19.195925+00:00Blinding, Ethics, and Safety in Psychedelic Clinical Trialspsychedelic clinical trials, blinding integrity, ethics in research, participant safety, institutional review board, FDA guidance, trial methodology, adverse event reporting, expectancy bias, regulatory standardshttps://mindmedicinelaw.com/briefing/ayahuasca-integration-in-yaqui-led-mental-health-care-sonora-mexico-20261009-48527The Psychedelic Journalen2026-10-10T15:06:01.022538+00:00Ayahuasca Integration in Yaqui-Led Mental Health Care, Sonora, Mexicoayahuasca, indigenous mental health, yaqui clinic, intercultural medicine, psychedelic care, mexico drug law, community-based care, indigenous sovereignty, psychedelic research, cultural adaptationhttps://mindmedicinelaw.com/briefing/fda-signals-openness-to-ibogaine-clinical-trials-in-the-us-20261009-48558The Psychedelic Journalen2026-10-10T15:05:43.767357+00:00FDA Signals Openness to Ibogaine Clinical Trials in the USfda, ibogaine, clinical trials, psychedelic research, addiction treatment, regulatory policy, schedule i substances, cardiac safety, drug developmenthttps://mindmedicinelaw.com/briefing/adverse-psychedelic-reactions-links-to-psychopathology-in-naturalistic-use-20261008-48861The Psychedelic Journalen2026-10-11T15:05:57.430147+00:00Adverse Psychedelic Reactions: Links to Psychopathology in Naturalistic Usepsychedelic adverse reactions, psychopathology, naturalistic use, harm reduction, public health policy, MDMA risks, contextual factors, user motivation, longitudinal research, screening protocolshttps://mindmedicinelaw.com/briefing/ai-driven-suicide-risk-prediction-in-bipolar-depression-implications-for-psyched-20261008-48568The Psychedelic Journalen2026-10-10T15:08:42.704054+00:00AI-Driven Suicide Risk Prediction in Bipolar Depression: Implications for Psychedelic Trialssuicide risk prediction, bipolar depression, machine learning, psychedelic clinical trials, risk stratification, FDA protocols, electronic health records, AI in psychiatry, trial inclusion criteriahttps://mindmedicinelaw.com/briefing/chiral-psychoactive-drugs-environmental-and-forensic-implications-20261008-48547The Psychedelic Journalen2026-10-10T15:08:24.472962+00:00Chiral Psychoactive Drugs: Environmental and Forensic Implicationschiral drugs, psychoactive substances, wastewater analysis, forensic chemistry, environmental monitoring, enantiomers, bioaccumulation, public health, stereoselectivity, regulatory policyhttps://mindmedicinelaw.com/briefing/interoceptive-training-in-psilocybin-therapy-for-cancer-patients-20261008-48529The Psychedelic Journalen2026-10-10T15:06:56.801088+00:00Interoceptive Training in Psilocybin Therapy for Cancer Patientspsilocybin therapy, cancer patients, interoceptive training, somatic practices, clinical trial design, depression and anxiety, phenomenological taxonomy, psychedelic-assisted therapy, therapeutic preparation, regulatory implicationshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-music-playlists-lack-phase-based-structure-20261008-48528The Psychedelic Journalen2026-10-10T15:06:39.263431+00:00Psilocybin Therapy Music Playlists Lack Phase-Based Structurepsilocybin therapy, music playlists, clinical trial protocols, pharmacodynamic phases, standardization, FDA regulation, psychedelic-assisted therapy, playlist curation, reproducibility, patient safetyhttps://mindmedicinelaw.com/briefing/lsd-alters-working-memory-brain-activity-in-mdd-rct-insights-20261008-48530The Psychedelic Journalen2026-10-10T15:06:21.806658+00:00LSD Alters Working Memory Brain Activity in MDD: RCT Insightslsd, major depressive disorder, working memory, fMRI, psychedelic clinical trials, cognitive effects, mood disorders, neuroimaging, trial design, regulatory policyhttps://mindmedicinelaw.com/briefing/lsd-s-effects-on-cortical-dynamics-mechanistic-insights-for-policy-and-research-20261007-48968The Psychedelic Journalen2026-10-11T15:06:13.596749+00:00LSD’s Effects on Cortical Dynamics: Mechanistic Insights for Policy and Researchlsd, cortical dynamics, fractal dimension, brain rhythms, psychedelic research, biomarkers, clinical trials, regulatory policy, neuroimaging, mechanistic evidence